Shionogi & Co., Ltd. presents new real-world data evaluating Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in adults with confirmed MBL-producing Enterobacterales infections at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich,17th-21st April, 2026.
Shionogi Press Release